Circumstances for The Diagnosis of Viral Hepatitis B at The Internal Medicine Department of The Sylvanus Olympio University Hospital in Lomé (Togo)

Lihanimpo Djalogue1*, Komi Dzidzonu Nemi2, Toyi Tchamdja1, Agbéko Kodjo Djagadou2, Abdou Razak Moukaila2, Komi Edem Mossi2, Lidaw Déassouwa Bawe3, Abago Balaka2 and Mohaman Awalou Djibril2

1Internal Medicine Department, Kara Teaching Hospital.

2Internal Medicine Department, Sylvanus Olympio Teaching Hospital, Togo.

3Maladies Infectieuses et Tropicales department, CHU Sylvanus Olympio de Lomé, Université de Lomé, Togo.

Citation: Djalogue L, Nemi KD, Tchamdja T, et al. Circumstances for The Diagnosis of Viral Hepatitis B at The Internal Medicine Department of The Sylvanus Olympio University Hospital in Lomé (Togo). J Med - Clin Res & Rev. 2020; 4(11): 1-3.

Objective: The aim of this study was to describe the different circumstances of discovery of viral hepatitis B in the Internal Medicine Department of the Sylvanus Olympio University Hospital in Lomé.

Method: This is a retrospective study conducted from January 1st 2017 to December 31st 2019 at the Medical Clinic and the B Medicine of this hospital center.

Results: During the study period, 4078 patients were received at the Medical Clinic and Medicine B. The HBs antigen was positive in 105 patients who had never been tested, representing a seroprevalence of 2.57%. The mean age of the patients was 36.37 years (extremes: 17 and 63 years) and the sex ratio (M/F) was 2, with the age range of 20 to 39 years being the most represented (61.90%). Viral hepatitis B was acute in 5 patients (4.76%) and chronic in 100 patients (95.23%). Infection was discovered by voluntary screening in 9 patients (8.85%) and incidentally diagnosed in 34 patients (32.38%). Symptoms were found in 43 patients (40.95%) and complications in 19 patients (18.09%) including decompensated cirrhosis of the liver (N=13) and hepatocellular carcinoma (N=6). The modes of decompensation of cirrhosis were oedematous syndrome and jaundice. Only 15 patients (15%) in the chronic phase of infection were able to achieve a viral load. The mean viral load was 36,319,839.86IU/ml with extremes ranging from 37 to 544,630,994IU/ml.

Conclusion: This study shows that the modes of revelation of viral hepatitis B in hospital settings in Lomé are dominated by clinical manifestations and chance discovery.

Keywords
Viral hepatitis B, Symptoms, Fortuitous discovery, Lomé (Togo).

Introduction
Viral hepatitis B is an infectious disease of the liver caused by the hepatitis B virus [1]. The acute infection is usually cured with the appearance of anti-HBs antibodies, which confer definitive immunity [2]. However, in 5-15% of adult subjects, the infection may progress to chronic infection, with a third of them expressing asymptomatic HBs antigen (HBsAg) with a favorable prognosis, and the remainder developing chronic hepatitis [2], which may be complicated by cirrhosis of the liver or hepatocellular carcinoma [3]. Viral hepatitis B is a major public health concern in both industrialized and developing countries, particularly in sub-Saharan Africa where it is endemic with an estimated prevalence of 8-20% [4]. In Togo, its average prevalence is over 11% [5]. Despite the existence of a vaccine against this virus, many people in Togo are still unimmunized in rural areas and therefore contaminated by chronic carriers, especially in the viral replication phase [6]. The purpose of this work is to describe the different
circumstances of diagnosis of this infection in the field of Internal Medicine in Lomé.

Methods
This is a retrospective study carried out in the Internal Medicine Department (Medicine B and Medical Clinic) of the CHU SO of Lomé. It was conducted over a period of three years from January 1, 2017 to December 31, 2019. Patients were included in this study, not only those aged 16 years and older in whom the diagnosis of viral hepatitis B was made in the department, but also those diagnosed in other departments of the hospital or in other health facilities and referred for better care. The diagnosis of viral hepatitis B was made on the basis of a positive HBs antigen by immunochromatography. Acute infection was reported in patients with IgM-type HBc antibodies and chronic infection in patients with total HBc antibodies. The parameters studied were seroprevalence, age, sex, circumstances of diagnosis of the infection and viral load of chronic carriers.

Results
During our study period, 4,078 patients were seen in Medicine B and at the Medical Clinic (outpatient and inpatient). The Hbs antigen was positive in 105 patients who had never been screened, representing a seroprevalence of 2.57% of unknown viral hepatitis B. The mean age of the patients was 36.37 years (extremes: 17 and 63 years) and the sex ratio (M/F) was 2, with the age group 20 to 39 years being the most represented (61.90%).

Viral hepatitis B was acute in 5 patients (4.76%) and chronic in 100 patients (95.23%).

Infection was discovered by voluntary screening in 9 patients (8.85%). It was incidentally diagnosed in 34 patients (32.38%) (Table 1).

Table 1: Patient Distribution by Incidental Discovery of Viral Hepatitis.

| Symptom                          | Number | %    |
|----------------------------------|--------|------|
| Health check-up                  | 18     | 52.94|
| Pre-marital check-up             | 5      | 14.70|
| Blood Donation                   | 5      | 14.70|
| Pregnancy check-up               | 3      | 8.82 |
| Leg Erysipelas + Deep Venous Thrombosis | 1 | 2.94 |
| Severe malaria                   | 1      | 2.94 |
| Skin abscess                     | 1      | 2.94 |
| Total                            | 34     | 100  |

Table 2: Distribution of patients by association or not of symptoms that revealed viral hepatitis B.

| Symptom                          | Number | %    |
|----------------------------------|--------|------|
| Asthenia                         | 17     | 39.53|
| Asthenia+Curvatures              | 6      | 13.95|
| Abdominal pain                   | 5      | 11.62|
| Dyspepsia                        | 5      | 11.62|
| Abdominal pain + Icterus         | 2      | 4.65 |
| Abdominal pain + Asthenia + Fever + Curvatures | 2 | 4.65 |
| Fever + Asthenia                 | 2      | 4.65 |
| Fever + Asthenia + Ictera        | 1      | 2.32 |
| Abdominal pain + Asthenia + Fever + Curvatures | 1 | 2.32 |
| Nasal discharge                  | 1      | 2.32 |
| Ictera                           | 1      | 2.32 |
| Headache                         | 1      | 2.32 |
| Total                            | 43     | 100  |

Discussion
This retrospective study allowed us to describe the different circumstances of discovery of viral hepatitis B in hospital settings in Lomé (Togo). The results show that the newly diagnosed viral hepatitis B in our department was 2.57%. This seroprevalence is certainly underestimated since screening was not systematic in all non-vaccinated patients admitted to the department. Nevertheless, it is close to the 3.25% reported in a Nephrology-Dialysis service in Mali [7]. The average age of our patients was 36.37 years and the majority was in the 20-39 age groups. This was therefore a very young population. Our result confirms the data from another Togolese series which also reported a predominance of the 20-39 age groups [8]. A predominance of the 25-44 age groups was observed in a Beninese series [9]. In Senegal, the mean age was 33 years in the study population of Diallo et al [10]. The predominance of young adults in our communities could be explained by the fact that this social stratum is more sexually active and therefore more exposed to risk behaviors than others. With regard to gender, the male preponderance observed in our study was also noted in the study by Diallo et al [10]. On the other hand, Tété-Benissan et al. reported a predominance of females in another Togolese series among the Ogo [5]. In our study, symptomatic acute viral hepatitis B was found in only 4.76% of the patients, thus joining the French data which estimate its incidence between 4.36% and 5.05% depending on the definitions used [11]. This low incidence of symptomatic acute viral hepatitis B in our study could be explained by its clinical manifestations, which are often treated as a malarial attack or a bacterial infection by inexperienced practitioners with a favorable evolution in the majority of cases, so that only patients with altered general condition are admitted to our department.

Symptomatic screening for any infectious and/or flu-like syndrome on admission would be desirable even in subjects with no risk factors, since the evolution may be towards fulminant hepatitis, which can be fatal in the absence of liver transplantation, or towards chronic hepatitis. This is the case of the 95.23% of our patients who were in the chronic phase of their infection at the time of diagnosis and in whom the symptoms revealed the infection in the majority of cases (40.95%) with asthenia followed by abdominal pain as the leading cause. Indeed, asthenia remains...
Cirrhosis of the liver and post-hepatitis B hepatocellular carcinoma pose a real public health problem in the world and particularly in Africa [10,14-19]. Treatment with nucleoside and nucleotide inhibitors can stabilize or even regress fibrosis lesions and reduce complications [19]. The last mode of revelation of infection in our series was voluntary screening in only 8.85% of cases. This low rate could be explained by the low awareness of our populations about this infection, resulting from the non-existence of a national program to fight this disease in our country.

**Conclusion**

Infection with the hepatitis B virus, which is little known, is frequent in hospitals in Lomé and its modes of revelation are dominated by clinical manifestations and chance discovery. A strong sensitization of the Togolese population through a national program of fight against viral hepatitis B is necessary in order to allow, on the one hand, prevention by vaccination of non-immune subjects and, on the other hand, early screening for early management in order to avoid or considerably reduce complications.

**References**

1. Fattorusso V, Ritter O. L’hépatite virale B. Vadémécum clinique du diagnostic au traitement. 18ème Edition Masson. Italie. 2016; 1202-1204.
2. Migliani R, Rousset D, Rakoto-Andrianarivelo M, et al. Infection par le virus de l’hépatite B un problème de santé publique à Madagascar. Arch Inst Pasteur Madagascar. 2000; 66: 50-54.
3. Kodjoh N. Situation de la lutte contre les hépatites virales B et C en Afrique. Med et Sante Trop. 2015; 25: 141-144.
4. World Health Organisation. WHO African Region. In Global policy report on the prevalence and control of viral hepatitis in WHO member states. Geneva. WHO. 2013; 10-29.
5. Tete-Benissan A, Degbe M, Salami-Osseni A, et al. Epidémiologie de l’hépatite B chez les Ogo du Togo Prévención et marqueurs sérologiques. J. Rech Sci Univ. Lomé Togo. 2018; 20: 89-102.
6. Dorkenoo AM, Kolou M, Sawadogo H, et al. Évaluation de la protection vaccinale contre le virus de l’hépatite B chez le personnel soignant hospitalier à Lomé. Med. Sante Trop. 2014; 24: 266-270.
7. Coulibaly AZMS. Prévalence des hépatites B et C dans le service de néphrologie et d’hémodialyse du CHU du Point G de Janvier 2010 à Décembre 2013. Thèse de Doctorat Université de Bamako Mali. 2014; 48-76.
8. Kolou M, Katawa G, Salou M, et al. High Prevalence of Hepatitis B Virus Infection in the Age Range of 20-39 Years Old Individuals in Lome. Open Virology J. 2017; 11: 1.
9. Lozes E, Dognon V, Bankole H, et al. Préalence de l’antigène HBs à l’hôpital de Zone d’Abomey-Calavi/Sô-Ava au Bénin de 2009 à 2014. Int J Biol Chem Sci. 2016; 10: 1832-1839.
10. Diallo S, Bassène ML, Gueye MN, et al. Hépatite virale B aspects cliniques paracliniques et évolutifs dans le service d’Hépato Gastroentérologie de l’Hôpital Aristide Le Dantec à propos de 728 cas. Pan Afr Med. 2018; 31: 82.
11. Brouard C, Bousquet V, Léon L, et al. Incidence de l’hépatite B aiguë symptomatique en France en 2010, enquête LaboHep 2010. Feuil de Biol. 2015; 322: 72-77.
12. Cadranel JF, Caron C, Collot G, et al. Hépatite B épidémiologie histoire naturelle biologie surveillance du traitement. Path. Biol. 1999; 47: 917-927.
13. Larsen C, Pioche C, Brouard C, et al. Hépatite B chronique prise en charge dans les pôles de référence depuis 2008 premiers résultats. BEH. 2010; 1: 1-5.
14. Dembele M, Maïga I, Minta D, et al. Étude de l’antigène HBs et des anticorps anti-virus de l’hépatite C au cours des hépatopathies chroniques dans des services hospitaliers à Bamako, Mali. Bull Soc Pathol Exot. 2004; 97: 161-164.
15. Balaka A, Djagadou KA, Tchamdja T, et al. Profil épidémiologique, clinique et évolutif de la cirrhose du foie en milieu hospitalier au Togo. Annales de l’Université Abdou Moumouni. 2016; 2: 37-41.
16. Ouattara B, Kra O, Kouassi L, et al. Etiology of ascites in a Department of Internal Medicine in Côte d’Ivoire Sub-Saharan Africa. Afr. J. Intern. Med. 2014; 3: 056-059.
17. Fartoux L, Serfaty L. Liver cirrhosis in adults: etiology and specific treatment. Rev Prat. 2005; 55: 1539-1548.
18. Anacreon S, Bischoff F, Frenkel J. Causes of mortality in patients with cirrhosis. Rev Med. Int. 2000; 22: 926-933.
19. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006; 295: 65-73.